B1NT34:BVMF
Biontech Se Bdr
R$28.11
arrow_upward
+1.52%(+0.42) 1D
Oct 19, 3:38:30 PM GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for B1NT34...
Open
R$27.95
High
R$28.11
Low
R$27.95
Mkt. cap
22.47B
Avg. vol.
1.45K
Volume
113.00
52-wk high
R$41.00
52-wk low
R$25.78
Shares outstanding
252.88M
No. of employees
8K
Open
R$27.95
High
R$28.11
Low
R$27.95
Mkt. cap
22.47B
Avg. vol.
1.45K
Volume
113.00
52-wk high
R$41.00
52-wk low
R$25.78
Shares outstanding
252.88M
No. of employees
8K
News stories
From web sources and news partners
The Motley Fool
·
23 hours ago
Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?
Yahoo Finance
·
2 days ago
Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About Biontech Se Bdr